Premium
BRENTUXIMAB VEDOTIN PLUS BENDAMUSTINE AS FIRST SALVAGE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA. EXPERIENCE AT DONOSTIA UNIVERSITY HOSPITAL, SPAIN
Author(s) -
Esquisabel B. Mendibil,
Segurola L. Ondarra,
Mongelos A. Altuna,
Alzola J. Iriondo,
Murua A. Zumalde,
Oyarzabal A. Arambarri,
Rois Pego N. F.,
Etxetxipia I. Zeberio
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.66_2881
Subject(s) - salvage therapy , bendamustine , medicine , refractory (planetary science) , brentuximab vedotin , regimen , surgery , autologous stem cell transplantation , oncology , chemotherapy , lymphoma , rituximab , hodgkin lymphoma , astrobiology , physics
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom